Record overview
Status and phase
Status: RECRUITING
Phase: PHASE1, PHASE2
Sponsor: Merck Sharp & Dohme LLC
Condition: Breast Neoplasms, Breast Cancer
NCT06686394
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.